Presenting at Psych Congress 2022, researchers assessed the safety and efficacy of COMP360 psilocybin therapy in adults with treatment-resistant depression.

Researchers sought to determine if lumateperone therapy improves quality of life and functional impairment in patients with bipolar disorder.

Researchers assessed clinician interactions with a prescription digital therapeutic dashboard, and the effect of this interaction on patient engagement and clinical outcomes.

Researchers evaluated changes in ADHD severity in children following treatment with SDX/d-MPH in a laboratory classroom setting.

Researchers conducted a survey that targeted clinicians’ perspectives on managing schizophrenia with oral antipsychotics vs long-acting injectable antipsychotic agents.

Researchers evaluated the efficacy of dextromorphan-bupropion among patients with major depressive disorder and comorbid anxiety.

Study authors assessed whether xanomeline-trospium could demonstrate a significant and meaningful improvement in Positive and Negative Syndrome Scale (PANSS) scores in patients with schizophrenia.

Researchers evaluated the effect of caffeine consumption with viloxazine extended-release in adults with attention-deficit/hyperactivity disorder.

Researchers analyzed the effects of using anticholinergics to treat tardive dyskinesia (TD) and developed recommendations for TD differentiation, appropriate use of anticholinergics, and more.

Researchers assessed the utility of implementing depression screening with the Patient Health Questionnaire in inpatient psychiatric care.